Chemistry:BAY-1158061
BAY-1158061, also known as HMI-115, is a monoclonal antibody against the prolactin receptor (PRLR) which is under development for the treatment of alopecia and endometriosis.[1][2] It is taken by long-lasting subcutaneous injection.[1][3] BAY-1158061 has been reported to promote hair growth in balding stump-tailed macaques.[4] The drug was first described in the scientific literature by 2018.[3][5][4] It is under development by Bayer and Hope Medicine.[1][2] As of June 2025, BAY-1158061 is in phase 2 clinical trials for alopecia and endometriosis.[1][2] Multiple phase 2 trials have been completed, including trials for both alopecia and endometriosis.[1] The chemical structure of BAY-1158061 does not yet appear to have been disclosed.[1]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "BAY 1158061". 28 June 2025. https://adisinsight.springer.com/drugs/800041931.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on BAY-1158061 with Synapse". 16 May 2025. https://synapse.patsnap.com/drug/243f64d8450d45d2890cc5948c28c74a.
- ↑ 4.0 4.1 May E, JODL SJ, Krätzschmar J, Otto C, "Prolactin receptor antibody for male and female pattern hair loss", WO patent 2019/011719, published 17 January 2019, assigned to Bayer Pharma AG
- ↑ "Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis?". Human Reproduction Update 24 (5): 577–598. September 2018. doi:10.1093/humupd/dmy020. PMID 29893860.
External links
Template:Prolactin receptor modulators
 |  |
